2023
1901. High Prevalence of Latent Tuberculosis Infection in a Malaysian Prison
Zhang L, Shenoi S, Kamarulzaman A, Dhaliwal S, Ahmad A, Altice F. 1901. High Prevalence of Latent Tuberculosis Infection in a Malaysian Prison. Open Forum Infectious Diseases 2023, 10: ofad500.1729. PMCID: PMC10677608, DOI: 10.1093/ofid/ofad500.1729.Peer-Reviewed Original ResearchLatent tuberculosis infectionPrevalence of LTBIRisk of LTBITB preventive therapyIndependent risk factorTuberculin skin testC-reactive proteinActive TBPreventive therapyTuberculosis infectionRisk factorsHigh prevalenceMultivariable logistic regressionOpioid use disorderRisk of hepatotoxicityChest X-rayDrug use historyPaucity of dataLTBI treatmentHCV infectionHepatitis CHepatitis BMedian ageBlood testsSkin test
2016
Confronting the HIV, Tuberculosis, Addiction, and Incarceration Syndemic in Southeast Asia: Lessons Learned from Malaysia
Culbert GJ, Pillai V, Bick J, Al-Darraji HA, Wickersham JA, Wegman MP, Bazazi AR, Ferro E, Copenhaver M, Kamarulzaman A, Altice FL. Confronting the HIV, Tuberculosis, Addiction, and Incarceration Syndemic in Southeast Asia: Lessons Learned from Malaysia. Journal Of Neuroimmune Pharmacology 2016, 11: 446-455. PMID: 27216260, PMCID: PMC5118227, DOI: 10.1007/s11481-016-9676-7.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyMalaysia's largest prisonIsoniazid preventive therapyLatent tuberculosis infectionStandardized treatment protocolMandatory HIV testingDrug treatment centersEvidence-based addiction treatmentEvidence-based interventionsLargest prisonReservoir of infectionActive diseaseActive tuberculosisPreventive therapyHIV testingTuberculosis infectionOpioid dependenceHIV treatmentRapid relapseMethadone maintenanceTreatment protocolClinical careHIVTreatment centersCompulsory drug treatment centers
2013
Integration of health services improves multiple healthcare outcomes among HIV-infected people who inject drugs in Ukraine
Bachireddy C, Soule MC, Izenberg JM, Dvoryak S, Dumchev K, Altice FL. Integration of health services improves multiple healthcare outcomes among HIV-infected people who inject drugs in Ukraine. Drug And Alcohol Dependence 2013, 134: 106-114. PMID: 24128379, PMCID: PMC3865106, DOI: 10.1016/j.drugalcdep.2013.09.020.Peer-Reviewed Original ResearchConceptsOpioid substitution therapyOpioid-dependent PWIDIsoniazid preventive therapyHealth-related qualityNeedles/syringesHIV-endemic regionsComposite scoreCross-sectional studyHealthcare quality indicatorsAntiretroviral therapyTuberculosis servicesPreventive therapySecondary outcomesHigher HRQoLMiddle-income countriesPrimary outcomePoor outcomeSubstitution therapyPotential confoundersTuberculosis treatmentHIV epidemicHIVHealth servicesPWIDOutreach settings
2012
Isoniazid preventive therapy in correctional facilities: a systematic review [Review article]
Al-Darraji HA, Kamarulzaman A, Altice FL. Isoniazid preventive therapy in correctional facilities: a systematic review [Review article]. The International Journal Of Tuberculosis And Lung Disease 2012, 16: 871-879. PMID: 22410101, DOI: 10.5588/ijtld.11.0447.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyIPT initiationPreventive therapySystematic reviewHuman immunodeficiency virus statusCompletion ratesPrevalent adverse reactionsCorrectional facilitiesIPT effectivenessTreatment interruptionActive tuberculosisViral hepatitisMiddle-income countriesTB controlAdverse reactionsRisk factorsVirus statusEligible studiesCommunity settingsTuberculosisLow-income countriesMajor causeJail settingsAdverse effectsInternational recommendations
2006
The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention
Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L. The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention. Clinical Infectious Diseases 2006, 43: s178-s183. PMID: 17109304, DOI: 10.1086/508181.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansIncidenceMaleNarcotic AntagonistsOpioid-Related DisordersRisk AssessmentSeverity of Illness IndexSubstance Abuse DetectionSubstance Abuse Treatment CentersSurvival AnalysisTreatment OutcomeUnited StatesConceptsHIV clinical care settingsHIV treatment outcomesClinical care settingsRole of buprenorphineOpioid dependenceTreatment outcomesCare settingsHuman immunodeficiency virus (HIV) infectionStudies of buprenorphineImmunodeficiency virus infectionHIV infection preventionUntreated opioid dependenceAntiretroviral therapyHIV carePreventive therapySecondary preventionAntiretroviral treatmentBuprenorphine treatmentHIV infectionOpportunistic infectionsSuccessful treatmentInfection preventionVirus infectionBuprenorphineInfected individuals